secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950103-23-007072
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q1 loss narrows to $22.7M; raises $72.8M in offering; pipeline advances
--------------------------------------------------------------------------------

- Revenue fell 66% YoY; Q1 operating loss $22.7M ($0.10 EPS) vs $23.9M ($0.12 EPS) in Q1 2022.
- Cash, equivalents and investments $125.4M; net proceeds of $72.8M from public offering at $1.75/share.
- Retired $29.5M of convertible notes; remaining $13.8M due July 2023 to be retired with restricted cash.
- Phase 1 PRGN-2012 data: 50% complete response; Phase 2 enrollment completed (N=23).
- First patient dosed with PRGN-3007 UltraCAR-T (PD-1 checkpoint); regained exclusive rights to CD19 and BCMA targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323007072/0000950103-23-007072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323007072/dp193579_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-007072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer